News Website

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.

Read Full Article

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.

Read Full Article

Endometrial cancer: MSS tumors may benefit from ICI when NK and T-cell activity is high - Vera Health

Endometrial cancer: MSS tumors may benefit from ICI when NK and T-cell activity is high Vera Health

Published: June 26, 2026, 7:57 a.m.

Read Full Article

An AI model decodes tumor mutations to predict treatment response - Drug Discovery News

An AI model decodes tumor mutations to predict treatment response Drug Discovery News

Published: June 1, 2026, 7:29 p.m.

Read Full Article

Analysis of Tumor-Associated Macrophages (TAM) Using Cluster of Differentiation 68 (CD68) Immunohistochemical Marker in Endometrial Carcinoma - Cureus

Analysis of Tumor-Associated Macrophages (TAM) Using Cluster of Differentiation 68 (CD68) Immunohistochemical Marker in Endometrial Carcinoma Cureus

Published: May 31, 2026, 4:44 p.m.

Read Full Article

Do estrogens really provoke tumors? A doctor explains - Українські Національні Новини (УНН)

Do estrogens really provoke tumors? A doctor explains Українські Національні Новини (УНН)

Published: May 28, 2026, 8:06 a.m.

Read Full Article

Woman, 35, told she was 'too young for cancer' before doctors discovered 28-lb. tumor the size of a watermelon - MSN

Woman, 35, told she was 'too young for cancer' before doctors discovered 28-lb. tumor the size of a watermelon MSN

Published: May 9, 2026, 5:09 p.m.

Read Full Article

Mom had her leg amputated after cancer diagnosis. Now she’s undergoing another ‘high risk’ procedure after tumors were found on her spine - MSN

Mom had her leg amputated after cancer diagnosis. Now she’s undergoing another ‘high risk’ procedure after tumors were found on her spine MSN

Published: April 25, 2026, 2:58 a.m.

Read Full Article

BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types - Fierce Biotech

BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types Fierce Biotech

Published: April 13, 2026, 9:10 a.m.

Read Full Article

SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer - OncLive

SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer OncLive

Published: April 12, 2026, 9:35 p.m.

Read Full Article

Latest Articles

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

Endometrial cancer: MSS tumors may benefit from ICI when NK and T-cell activity is high - Vera Health

An AI model decodes tumor mutations to predict treatment response - Drug Discovery News

Analysis of Tumor-Associated Macrophages (TAM) Using Cluster of Differentiation 68 (CD68) Immunohistochemical Marker in Endometrial Carcinoma - Cureus

Do estrogens really provoke tumors? A doctor explains - Українські Національні Новини (УНН)

Woman, 35, told she was 'too young for cancer' before doctors discovered 28-lb. tumor the size of a watermelon - MSN

Mom had her leg amputated after cancer diagnosis. Now she’s undergoing another ‘high risk’ procedure after tumors were found on her spine - MSN

BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types - Fierce Biotech

SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer - OncLive

Subscribe to Our Newsletter